Journal of Oncological Sciences · 2017 · 109 citations · 34 references
MedicineOncologyPharmacologyCancer PharmacologyImmunotherapyMolecular OncologyCancer ImmunotherapyCheckpoint Inhibitor TherapyEnzyme InhibitionImmune Checkpoint InhibitorsImmune Checkpoint ModulationImmune Checkpoint RegulationAntimicrobial MetabolitesCheckpoint Modulation In CancerImmunosuppressive CompoundsImmunosuppressive FunctionIndoleamine 2, 3-Dioxygenase PathwayRate LimitingTryptophan MetabolismTryptophan Oxidation
Tryptophan (Trp) is one of the important essential amino acids and Kynurenine pathway (KP) is the first and rate limiting step of degrading Trp to active metabolites. Recent studies showed that KP metabolites have antimicrobial and immunosuppressive roles. The main controller enzyme of this pathway is indoleamine-2,3-dioxygenase (IDO). IDO is an intracellular monomeric, heme-containing enzyme that controls the Trp breakdown in the KP. In this review, we discuss IDO functions on cancer progression and prognosis, and possible therapeutic aspects of inhibition of IDO on cancer immunotherapy.
34
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
Martin Reck, Delvys Rodríguez‐Abreu, Andrew Robinson et al. · New England Journal of Medicine · 2016 · 10.1K citations · Full text
Medicine, Oncology, Pharmacology +17
Pembrolizumab versus Ipilimumab in Advanced Melanoma
Caroline Robert, Jacob Schachter, Georgina V. Long et al. · New England Journal of Medicine · 2015 · 5.8K citations · Full text
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Robert L. Ferris, George R. Blumenschein, Jérôme Fayette et al. · New England Journal of Medicine · 2016 · 5.1K citations · Full text
Medicine, Oncology, Metastasis +5
Inhibition of T Cell Proliferation by Macrophage Tryptophan Catabolism
David H. Munn, Ebrahim Shafizadeh, John T. Attwood et al. · The Journal of Experimental Medicine · 1999 · 1.6K citations · Full text